Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD).
Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
The company also develops GEM307 for treatment of systemic diseases.
Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 10, 22 | -0.08 Increased by +98.14% | -0.09 Increased by +11.11% |
| Aug 11, 22 | -1.60 Increased by +57.89% | -2.00 Increased by +20.00% |
| May 6, 22 | -3.50 Increased by +40.68% | -3.01 Decreased by -16.28% |
| Mar 10, 22 | -4.10 Decreased by -101.97% | -4.97 Increased by +17.51% |
| Nov 15, 21 | -4.30 Decreased by -10.65 K% | -4.73 Increased by +9.09% |
| Aug 12, 21 | -3.80 Decreased by -112.48% | -4.00 Increased by +5.00% |
| May 13, 21 | -5.90 Decreased by -290.39% | -3.65 Decreased by -61.64% |
| Jan 19, 21 | -2.03 Decreased by -34.32% | -11.80 Increased by +82.80% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 22 | 0.00 Decreased by N/A% | -3.28 M Increased by +82.34% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -7.09 M Increased by +56.89% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -15.23 M Increased by +20.04% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -17.82 M Decreased by -2.09 K% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -18.55 M Decreased by -85.45% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 21 | 0.00 Decreased by N/A% | -16.45 M Decreased by -142.83% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 21 | 0.00 Decreased by N/A% | -19.05 M Decreased by -95.44% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 20 | 0.00 - | -812.50 K - | Decreased by N/A% - |